Sage Therapeutics — FY2024 Earnings Presentation
10 slides from Sage Therapeutics's earnings presentation, Feb 11, 2025
Slide 1: Fourth Quarter and Full Year 2024 Financial Results
Fourth Quarter and Full Year 2024 Financial Results February 11, 2025
Slide 2: Safe Harbor Statement
• Safe Harbor Statement The slides presented today and the accompanying oral presentations contain forward-looking statements, − We may encounter unexpected safety or tolerability issues with respect to any of our product candidates or which may be identified by the use of words such as “may,” “migh
Slide 3: Sage Therapeutics call participants
Sage Therapeutics call participants Barry Greene Chris Benecchi Laura Gault Mike Quirk Chief Executive Officer Chief Operating Officer Chief Medical Officer Chief Scientific Officer Sage The rapeutics © 2025 3
Slide 4: Our vision and mission
O U R V I SI O N Fearlessly lead the way to create a world with better brain health. OU R M IS S I ON person can thrive Pioneer solutions to deliver life-changing brain health medicines, so every person can thrive. Sage The rapeutics © 2025 4
Slide 5: 2025 core priorities
2025 core priorities 1 2 3 Continued Targeted Financial Commercial Pipeline Focus Momentum Strategically invest in Develop novel programs in Optimize ZURZUVAE commercialization of diseases with high unmet need in commercialization in PPD, pipeline ZURZUVAE® in highly Neurodevelopmental Disorders & p
Slide 6: ZURZUVAE – think big, start focused, scale with success
ZURZUVAE – think big, start focused, scale with success >6,600 women with PPD treated with ZURZUVAE in FY 2024 Majority of ZURZUVAE patients received ZURZUVAE as their first new treatment for PPD >90% ~80% >95% Commercial and aided brand of prescriptions Medicaid awareness among were written lives a
Slide 7: Scaling PPD commercialization efforts with success in 2025
Scaling PPD commercialization efforts with success in 2025 SALESFORCE EXPANSION HCP & PATIENT WEBSITES Joint salesforce expansion to cover a 1 wider reach of HCPs who treat PPD 2 Build on ZURZUVAE branded media Expand social media influencer 3 campaigns/DTC Increase investment in disease state 4 awa
Slide 8: Fourth quarter and full year 2024 and 2023 financial results
Fourth quarter and full year 2024 and 2023 financial results Item Q4 ’24 Q4 ’23 Full Year ’24 Full Year ’23 Product revenue, net $0.4M $22.9M $3.6M $10.5M License and milestone revenue - related party* $0.0M $75.0M $0.0M $75.0M Collaboration revenue - related party $11.4M $0.8M $36.1M $0.8M Other Co
Slide 9: Our pipeline
Our pipeline COMPOUND INDICATIONS PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 FDA APPROVED COLLABORATORS Neuropsychiatry ZURZUVAE®* Postpartum (zuranolone) Oral CIV Depression MA RKE T ED Neurodevelopmental Disorders Behavioral symptoms SAGE-319 associated with P HAS E 1 GABA Hypofunction neurodevelopmenta
Slide 10: Q&A
Q&A Sage The rapeutics © 2025 10